Inclusion Criteria

1. Patient gives voluntary written informed consent to participate in the study.
2. Patients with a diagnosis of ILD based on computed tomography imaging, including:

1. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis
2. Connective tissue disease-associated ILD with forced vital capacity (FVC) <70%
3. Hypersensitivity pneumonitis
4. Scleroderma-related ILD
5. Autoimmune ILD
6. Nonspecific interstitial pneumonia
7. Occupational lung disease
8. Combined pulmonary fibrosis and emphysema
3. Patients must have at least 2 signs or symptoms suggestive of PH, as specified by the study protocol.

Exclusion Criteria

1. Prior RHC with mPAP >20 mmHg.
2. Currently on a Food and Drug Administration (FDA)-approved pulmonary arterial hypertension medication.
3. Diagnosed with chronic obstructive pulmonary disease.
4. Uncontrolled or untreated sleep apnea.
5. Pulmonary embolism within the past 3 months.
6. History of ischemic heart disease or left-sided myocardial dysfunction within 12 months of Screening, defined as left ventricular ejection fraction <40% or pulmonary capillary wedge pressure >15 mmHg.
7. Any other clinical features that, in the opinion of the Investigator, might adversely affect interpretation of study data or study safety, or make the patient unsuitable for RHC.